A New Paradigm in Drug Discovery
Fast, high-resolution data that provides unparalleled insights into protein structure, motion and binding.
PLIMB: Plasma Induced Modification of Biomolecules
PLIMB is a novel and groundbreaking technology for performing hydroxyl radical protein footprinting–a technique which utilizes mass spectrometry to provide structural data of a protein in its native solution and conformation. PLIMB utilizes plasma to generate microsecond bursts of hydroxyl radicals, which modify and label solvent-accessible regions of a protein.
PLIMB Benefits:
- No need for protein crystallization or mutations
- In solution protein analysis in native state
- Sub-microsecond timescale hydroxyl generation
- Low sample consumption (<5 ug per sample)
- Precise Temperature control (-10 to 800C)
- High throughput analysis: automatic 96-well plate exposure
- Protein Compatibility- can be used with challenging protein targets (membrane proteins, GPCR, etc.)
Benefits of Immuto’s Services:
- Fast Turnaround (2-3 weeks)- allows for rapid iteration and reduces cycle time in lead optimization and ultimately increases the number and range of programs that can be run in parallel.
- Reduce Cost - can be performed on many lead candidates
- Develop better/ more effective lead candidates and reduce risk of clinical trial failures
- Faster IP fillings with strong epitope claims
- Native Analysis- native structure and protein conditions for biologically relevant results
- Protein Compatibility- can be used with challenging protein targets (membrane proteins, GPCR, etc.)
We integrate innovative, cutting-edge technologies that enables us to effectively analyze large sets of protein-protein interactions with high throughput and resolution which:
Reduces cycle time in lead optimization by allowing
rapid iteration
Reduces cost of early stage Drug Discovery Programs
Increases the number of shots on goal
Reduces risk of clinical trial failures
Allows rapid IP fillings with strong epitope claims
PLIMB How it works
PLIMB works by labelling the proteins in solution through exposure to hydroxyl (OH) radicals. Hydroxyl radicals are highly reactive species which are generated by our proprietary plasma reactor in sub-microsecond bursts, in order to ensure structural stability during exposure. During exposure, plasma-generated radicals will label solvent-accessible side chains of the protein through a permanent covalent modification, capturing structural details of the protein in its native, in-solution state. Following exposure, proteins will then be digested and prepared for mass spectrometry analysis. Data analysis can then be used to calculate the relative abundance of modified and unmodified species on a peptide or single amino acid level. This information can then be used to assess structural differences between a protein in two distinct conditions, including bound and unbound to an antibody or ligand.
The Proof Is in the Papers.
Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.
What the Data Looks Like
Crystal Structure: PLIMB technology enables precise mapping of both the epitope interactions of a therapeutic and its target, as well as allosteric conformational changes upon binding in a single experiment. Understanding the full characteristics of binding is essential to optimize the efficacy of a pharmaceutical candidate.
% Modification: By monitoring the degree of PLIMB-induced labelling on the target protein in its bound and unbound state, changes in solvent accessibility over various regions of a protein can be detected. Based on these changes, localization and characterization of the epitope interactions and allosteric conformational changes can be achieved in a simple, yet robust experimental process.
